

Anders SÅnnerborg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1882265/publications.pdf>

Version: 2024-02-01

346
papers

14,947
citations

23500

58
h-index

29081

104
g-index

350
all docs

350
docs citations

350
times ranked

16890
citing authors

#	ARTICLE	IF	CITATIONS
1	Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. <i>Cell</i> , 2020, 183, 158-168.e14.	13.5	1,561
2	Randomised, double-blind, placebo-controlled trial of interferon β with and without ribavirin for chronic hepatitis C. <i>Lancet</i> , The, 1998, 351, 83-87.	6.3	623
3	Late presentation of HIV infection: a consensus definition. <i>HIV Medicine</i> , 2011, 12, 61-64.	1.0	378
4	Activation, exhaustion, and persistent decline of the antimicrobial MR1-restricted MAIT-cell population in chronic HIV-1 infection. <i>Blood</i> , 2013, 121, 1124-1135.	0.6	347
5	Gut Microbiota Linked to Sexual Preference and HIV Infection. <i>EBioMedicine</i> , 2016, 5, 135-146.	2.7	328
6	T-bet and Eomes Are Differentially Linked to the Exhausted Phenotype of CD8+ T Cells in HIV Infection. <i>PLoS Pathogens</i> , 2014, 10, e1004251.	2.1	273
7	Gut microbiota diversity predicts immune status in HIV-1 infection. <i>Aids</i> , 2015, 29, 2409-2418.	1.0	238
8	HIV in pregnant women and their offspring: evidence for late transmission. <i>Lancet</i> , The, 1991, 338, 203-207.	6.3	222
9	European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 394-407.	4.6	218
10	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 565-575.	4.6	217
11	Transmission of Drug-Resistant HIV Is Stabilizing in Europe. <i>Journal of Infectious Diseases</i> , 2009, 200, 1503-1508.	1.9	213
12	Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7 and Defective in HIV-1 Infection. <i>PLoS Pathogens</i> , 2015, 11, e1005072.	2.1	204
13	Interferon-Alpha and Tumor Necrosis Factor-Alpha in Serum of Patients in Various Stages of HIV-1 Infection. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 375-380.	0.5	201
14	Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. <i>Journal of Virology</i> , 1987, 61, 2017-2023.	1.5	164
15	Limited humoral immunity in hepatitis C virus infection. <i>Gastroenterology</i> , 1999, 116, 135-143.	0.6	147
16	Subtype-specific problems with quantification of plasma HIV-1 RNA. <i>Aids</i> , 1997, 11, 859-865.	1.0	146
17	Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. <i>Pharmacogenetics and Genomics</i> , 2006, 16, 191-198.	0.7	145
18	Feasibility and Effectiveness of Indicator Condition-Guided Testing for HIV: Results from HIDES I (HIV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.1	145

#	ARTICLE	IF	CITATIONS
19	Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. <i>Clinical Infectious Diseases</i> , 2016, 62, 655-663.	2.9	135
20	Phenotypic Characteristics of Human Immunodeficiency Virus Type 1 Subtype C Isolates of Ethiopian AIDS Patients. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 647-653.	0.5	133
21	HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. <i>Retrovirology</i> , 2013, 10, 7.	0.9	129
22	Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. <i>Aids</i> , 2002, 16, 683-692.	1.0	127
23	Increased Production of Malondialdehyde in Patients with HIV Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1988, 20, 287-290.	1.5	121
24	Antigen detection in primary HIV infection. <i>BMJ: British Medical Journal</i> , 1988, 296, 238-240.	2.4	117
25	Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. <i>Aids</i> , 2000, 14, 2333-2339.	1.0	116
26	Isolation of human immunodeficiency virus (HIV) from plasma during primary HIV infection. <i>Journal of Medical Virology</i> , 1987, 23, 67-73.	2.5	115
27	Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing. <i>Antiviral Therapy</i> , 2004, 9, 829-848.	0.6	114
28	Impact of Therapeutic Immunization on HIV-1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection. <i>Journal of Infectious Diseases</i> , 2005, 192, 607-617.	1.9	111
29	Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets. <i>HIV Medicine</i> , 2017, 18, 305-307.	1.0	108
30	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. <i>Clinical Infectious Diseases</i> , 2018, 66, 893-903.	2.9	105
31	Efficient isolation of HIV from plasma during different stages of HIV infection. <i>Journal of Medical Virology</i> , 1988, 26, 23-32.	2.5	103
32	Perforin is not co-expressed with granzyme A within cytotoxic granules in CD8 T lymphocytes present in lymphoid tissue during chronic HIV infection. <i>Aids</i> , 1999, 13, 1295-1303.	1.0	99
33	Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. <i>Aids</i> , 2002, 16, 1039-1044.	1.0	99
34	Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. <i>Journal of Medical Virology</i> , 1995, 46, 43-47.	2.5	98
35	Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. <i>Hepatology</i> , 1995, 21, 918-922.	3.6	95
36	Viral dynamics in primary HIV-1 infection. <i>Aids</i> , 2000, 14, 2283-2291.	1.0	92

#	ARTICLE	IF	CITATIONS
37	Effect of N -acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 457-461.	0.8	91
38	Severe functional impairment and elevated PD α expression in CD1d α -restricted NKT cells retained during chronic HIV α infection. <i>European Journal of Immunology</i> , 2009, 39, 902-911.	1.6	91
39	Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. <i>Journal of Medical Virology</i> , 1993, 41, 99-102.	2.5	87
40	Full-Length Sequence of an Ethiopian Human Immunodeficiency Virus Type 1 (HIV-1) Isolate of Genetic Subtype C. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1329-1339.	0.5	86
41	Long Terminal Repeat Promoter/Enhancer Activity of Different Subtypes of HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1293-1303.	0.5	85
42	Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. <i>Aids</i> , 1998, 12, F203-F209.	1.0	82
43	Neutralizing Antibody Response During Human Immunodeficiency Virus Type 1 Infection: Type and Group Specificity and Viral Escape. <i>Journal of General Virology</i> , 1993, 74, 855-863.	1.3	80
44	Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers. <i>Scientific Reports</i> , 2017, 7, 6269.	1.6	79
45	Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. <i>Aids</i> , 1998, 12, 2007-2015.	1.0	77
46	Early Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir as Maintenance Monotherapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 44, 417-422.	0.9	74
47	Genetic Evidence for Mother α to α Infant Transmission of Hepatitis G Virus. <i>Journal of Infectious Diseases</i> , 1997, 176, 281-285.	1.9	71
48	Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in swedish blood donors. <i>Journal of Medical Virology</i> , 1993, 39, 57-61.	2.5	69
49	HIV-1 transmission between MSM and heterosexuals, and increasing proportions of circulating recombinant forms in the Nordic Countries. <i>Virus Evolution</i> , 2016, 2, vew010.	2.2	68
50	HIV viral load and response to antileishmanial chemotherapy in co-infected patients. <i>Aids</i> , 1999, 13, 1921-1925.	1.0	66
51	Antiretroviral therapy may improve sensory function in HIV-infected patients. <i>Neurology</i> , 2000, 54, 2120-2127.	1.5	66
52	Isolation Frequency of Human Immunodeficiency Virus from Cerebrospinal Fluid and Blood of Patients with Varying Severity of HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1988, 4, 351-358.	0.5	65
53	Reduced Levels of D-dimer and Changes in Gut Microbiota Composition After Probiotic Intervention in HIV-Infected Individuals on Stable ART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, 329-337.	0.9	65
54	Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals. <i>Scientific Reports</i> , 2017, 7, 40354.	1.6	65

#	ARTICLE	IF	CITATIONS
55	Metabolic Perturbation Associated With COVID-19 Disease Severity and SARS-CoV-2 Replication. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100159.	2.5	65
56	Indinavir-based treatment of HIV-1 infected patients: efficacy in the central nervous system. <i>Aids</i> , 1999, 13, 1227-1232.	1.0	64
57	Molecular Epidemiology of HIV-1 Subtypes in India: Origin and Evolutionary History of the Predominant Subtype C. <i>PLoS ONE</i> , 2012, 7, e39819.	1.1	64
58	Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. <i>Aids</i> , 2007, 21, 565-574.	1.0	63
59	Global Dispersal Pattern of HIV Type 1 Subtype CRF01_AE: A Genetic Trace of Human Mobility Related to Heterosexual Sexual Activities Centralized in Southeast Asia. <i>Journal of Infectious Diseases</i> , 2015, 211, 1735-1744.	1.9	62
60	Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. <i>Aids</i> , 2010, 24, 1733-1737.	1.0	60
61	The global spread of HIV-1 subtype B epidemic. <i>Infection, Genetics and Evolution</i> , 2016, 46, 169-179.	1.0	60
62	Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. <i>Infection, Genetics and Evolution</i> , 2013, 18, 125-131.	1.0	58
63	Low Levels of Perforin Expression in CD8+T Lymphocyte Granules in Lymphoid Tissue during Acute Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Infectious Diseases</i> , 2002, 185, 1355-1358.	1.9	56
64	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	1.3	56
65	Low Prevalence of Transmitted Drug Resistance in Patients Newly Diagnosed with HIV-1 Infection in Sweden 2003-2010. <i>PLoS ONE</i> , 2012, 7, e33484.	1.1	56
66	Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells. <i>Journal of Immunological Methods</i> , 1998, 214, 97-111.	0.6	55
67	Painful and non-painful neuropathy in HIV-infected patients: an analysis of somatosensory nerve function. <i>European Journal of Pain</i> , 2003, 7, 23-31.	1.4	55
68	Nosocomial transmission of hepatitis C virus. <i>Infection</i> , 1997, 25, 74-77.	2.3	54
69	CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4 β -hydroxycholesterol levels. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 775-781.	0.8	54
70	Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naïve patients. <i>Aids</i> , 1998, 12, 2369-2375.	1.0	53
71	Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe. <i>Journal of Infectious Diseases</i> , 2013, 207, 1216-1220.	1.9	53
72	Limited cross-border infections in patients newly diagnosed with HIV in Europe. <i>Retrovirology</i> , 2013, 10, 36.	0.9	52

#	ARTICLE	IF	CITATIONS
73	Characterization of the viral population during primary HIV-1 infection. <i>Aids</i> , 1998, 12, 839-847.	1.0	50
74	Selecting anti-HIV therapies based on a variety of genomic and clinical factors. <i>Bioinformatics</i> , 2008, 24, i399-i406.	1.8	50
75	Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels. <i>BMC Infectious Diseases</i> , 2016, 16, 305.	1.3	50
76	Detection of hepatitis C virus RNA in the cell fraction of saliva before and after oral surgery. <i>Journal of Medical Virology</i> , 1995, 45, 223-226.	2.5	49
77	Cerebrospinal Fluid Mononuclear Cell Counts Influence CSF HIV-1 RNA Levels. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 17, 214-219.	0.3	49
78	Temporal Trends in the Swedish HIV-1 Epidemic: Increase in Non-B Subtypes and Recombinant Forms over Three Decades. <i>PLoS ONE</i> , 2014, 9, e99390.	1.1	48
79	Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. <i>Clinical and Experimental Immunology</i> , 2002, 127, 486-494.	1.1	47
80	Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences. , 1996, 49, 155-160.		46
81	The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges. <i>Clinical Infectious Diseases</i> , 2017, 64, 1644-1656.	2.9	46
82	Variation of Hepatitis C Virus Hypervariable Region 1 in Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 1997, 175, 938-943.	1.9	45
83	Comparison of 3 Quantitative HCV RNA Assays - Accuracy of Baseline Viral Load to Predict Treatment Outcome in Chronic Hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 1998, 30, 441-446.	1.5	45
84	Adherence to treatment in Swedish HIV-infected patients. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 605-616.	0.7	45
85	Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy. <i>PLoS ONE</i> , 2008, 3, e3470.	1.1	45
86	Detection of immunoglobulin M antibody in primary human immunodeficiency virus infection. <i>Aids</i> , 1988, 2, 11-16.	1.0	44
87	Predicting Response to Antiretroviral Treatment by Machine Learning: The EuResist Project. <i>Intervirology</i> , 2012, 55, 123-127.	1.2	43
88	Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. <i>BMC Infectious Diseases</i> , 2014, 14, 407.	1.3	43
89	Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden. <i>Lancet HIV</i> , 2016, 3, e166-e174.	2.1	43
90	GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. <i>Frontiers in Microbiology</i> , 2019, 10, 1227.	1.5	43

#	ARTICLE	IF	CITATIONS
91	HIV Care in the Swedish-Danish HIV Cohort 1995-2010, Closing the Gaps. PLoS ONE, 2013, 8, e72257.	1.1	42
92	Rapid Grouping of HIV-1 Infection in Subtypes A to E by V3 Peptide Serotyping and Its Relation to Sequence Analysis. Biochemical and Biophysical Research Communications, 1994, 205, 1658-1664.	1.0	41
93	Distribution of the CCR5 gene 32 base pair deletion and SDF1-3'A variant in healthy individuals from different populations. Immunogenetics, 1998, 48, 417-419.	1.2	40
94	Intracellular high mobility group B1 protein (HMGB1) represses HIV-1 LTR-directed transcription in a promoter- and cell-specific manner. Virology, 2003, 314, 179-189.	1.1	40
95	Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2phenoâ€”THEO on a Large Clinical Database. Journal of Infectious Diseases, 2009, 199, 999-1006.	1.9	40
96	Deficiencies in the health care system contribute to a high rate of late <scp>HIV</scp> diagnosis in Sweden. HIV Medicine, 2016, 17, 425-435.	1.0	40
97	Indinavir in cerebrospinal fluid of HIV-1-infected patients. Lancet, The, 1997, 350, 1823.	6.3	39
98	HIV-1 Subtype Is an Independent Predictor of Reverse Transcriptase Mutation K65R in HIV-1 Patients Treated with Combination Antiretroviral Therapy Including Tenofovir. Antimicrobial Agents and Chemotherapy, 2013, 57, 1053-1056.	1.4	39
99	Combined Treatment of Symptomatic Human Immunodeficiency Virus Type 1 Infection with Native Interferon-Â and Zidovudine. Journal of Infectious Diseases, 1991, 163, 710-715.	1.9	38
100	Dynamics of the HIV-1 Subtype Distribution in the Swedish HIV-1 Epidemic during the Period 1980 to 1993. AIDS Research and Human Retroviruses, 1997, 13, 343-345.	0.5	37
101	Quantitative Detection of Brain Aberrations in Human Immunodeficiency Virus Type I-Infected Individuals by Magnetic Resonance Imaging. Journal of Infectious Diseases, 1990, 162, 1245-1251.	1.9	36
102	Immunoglobulin M reactivity towards the immunologically active region sp75 of the core protein of hepatitis C virus (HCV) in chronic HCV infection. Journal of Medical Virology, 1993, 39, 325-332.	2.5	36
103	Quantification of Human Immunodeficiency Virus Type 1 Proviral DNA by the TaqMan Real-Time PCR Assay. Journal of Clinical Microbiology, 2002, 40, 3883-3884.	1.8	36
104	HMGB1 activates replication of latent HIV-1 in a monocytic cell-line, but inhibits HIV-1 replication in primary macrophages. Cytokine, 2006, 34, 17-23.	1.4	36
105	Serum Hepatitis C Virus RNA Levels in Chronic Hepatitis C-Importance for outcome of interferon alfa-2b treatment. Scandinavian Journal of Infectious Diseases, 1994, 26, 263-270.	1.5	35
106	Assessing and achieving readiness to initiate HIV medication. Patient Education and Counseling, 2006, 62, 21-30.	1.0	35
107	Survival and causes of death among HIV-infected patients starting antiretroviral therapy in north-eastern Vietnam. Scandinavian Journal of Infectious Diseases, 2012, 44, 201-208.	1.5	34
108	Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia. Journal of Virological Methods, 1994, 47, 1-13.	1.0	33

#	ARTICLE	IF	CITATIONS
109	Variation in the hepatitis C virus NS5a region in relation to hypervariable region 1 heterogeneity during interferon treatment. , 1998, 56, 33-38.		32
110	Expansion of CD7 ^{low} and CD7 ^{negative} CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. <i>Blood</i> , 2004, 104, 3672-3678.	0.6	32
111	Kinetics of plasma cytokines and chemokines during primary HIV-1 infection and after analytical treatment interruption. <i>HIV Medicine</i> , 2009, 10, 94-102.	1.0	32
112	Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). <i>HIV Medicine</i> , 2011, 12, 211-218.	1.0	32
113	Utility of Proteomics in Emerging and Re-Emerging Infectious Diseases Caused by RNA Viruses. <i>Journal of Proteome Research</i> , 2020, 19, 4259-4274.	1.8	32
114	Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group. <i>PLoS ONE</i> , 2014, 9, e94495.	1.1	32
115	Monophyletic HIV Type 1 CRF02-AG in a Nosocomial Outbreak in Benghazi, Libya. <i>AIDS Research and Human Retroviruses</i> , 2002, 18, 727-732.	0.5	31
116	Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. <i>Aids</i> , 2018, 32, 469-476.	1.0	31
117	Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 339-350.	2.4	31
118	Elevated plasma levels of high mobility group box protein 1 in patients with HIV-1 infection. <i>Aids</i> , 2007, 21, 869-871.	1.0	30
119	Kinetics of Microbial Translocation Markers in Patients on Efavirenz or Lopinavir/r Based Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e55038.	1.1	30
120	Occasional spontaneous clearance of chronic hepatitis C virus in HIV-infected individuals. <i>Journal of Hepatology</i> , 2014, 61, 957-961.	1.8	30
121	Limited immune surveillance in lymphoid tissue by cytolytic CD4 ⁺ T cells during health and HIV disease. <i>PLoS Pathogens</i> , 2018, 14, e1006973.	2.1	30
122	Detection of human immunodeficiency virus-1 by polymerase chain reaction and virus cultivation. <i>Journal of Medical Virology</i> , 1990, 31, 234-240.	2.5	29
123	Detection of HIV-1 DNA and Infectious Virus in Cerebrospinal Fluid. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 369-373.	0.5	29
124	A Novel Ribozyme Target Site Located in the HIV-1 Nef Open Reading Frame. <i>Virology</i> , 1996, 219, 161-169.	1.1	29
125	HIV-1 exposed dendritic cells show increased pro-inflammatory cytokine production but reduced IL-1ra following lipopolysaccharide stimulation. <i>Aids</i> , 1999, 13, 2013-2021.	1.0	29
126	Pain in ambulatory HIV-infected patients with and without intravenous drug use. <i>European Journal of Pain</i> , 1999, 3, 157-164.	1.4	29

#	ARTICLE	IF	CITATIONS
127	Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. <i>AIDS Research and Therapy</i> , 2009, 6, 15.	0.7	29
128	Parvovirus B19 infection in HIV-1 infected patients with anemia. <i>Infection</i> , 1994, 22, 356-358.	2.3	28
129	Multiple Enhancer Motifs in HIV Type 1 Strains from Ethiopia. <i>AIDS Research and Human Retroviruses</i> , 1995, 11, 761-764.	0.5	28
130	Implications of the release of high-mobility group box 1 protein from dying cells during human immunodeficiency virus type 1 infection in vitro. <i>Journal of General Virology</i> , 2010, 91, 1800-1809.	1.3	28
131	Cost-efficient HIV-1 drug resistance surveillance using multiplexed high-throughput amplicon sequencing: implications for use in low- and middle-income countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3349-3355.	1.3	28
132	Transcriptomics and Targeted Proteomics Analysis to Gain Insights Into the Immune-control Mechanisms of HIV-1 Infected Elite Controllers. <i>EBioMedicine</i> , 2018, 27, 40-50.	2.7	28
133	Pretreatment drug resistance in a large countrywide Ethiopian HIV-1C cohort: a comparison of Sanger and high-throughput sequencing. <i>Scientific Reports</i> , 2018, 8, 7556.	1.6	28
134	DECLINING LEVELS OF HIV P24 ANTIGEN IN SERUM DURING TREATMENT WITH FOSCARNET. <i>Lancet, The</i> , 1988, 331, 1052.	6.3	27
135	Transmission of zidovudine-resistant HIV-1. <i>Aids</i> , 1993, 7, 1684-1685.	1.0	27
136	Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors. <i>Viruses</i> , 2014, 6, 3535-3562.	1.5	27
137	Dynamic analysis of heterogeneous hepatitis C virus populations by direct solid-phase sequencing. <i>Journal of Clinical Microbiology</i> , 1995, 33, 1870-1874.	1.8	27
138	Nitroblue Tetrazolium (NBT) Reduction by Neutrophilic Granulocytes in Patients with HTLV-III Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1986, 18, 101-103.	1.5	26
139	Intrauterine and intrapartum transmission of HIV. <i>Lancet, The</i> , 1992, 339, 245-246.	6.3	25
140	Nonsynonymous Mutations within the Human Immunodeficiency Virus Type 1 p17 Gene Are Clustered to Sequences Binding to the Host Human Leukocyte Antigen Class I Molecules. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 241-248.	0.5	25
141	Longitudinal Quantification of Human Immunodeficiency Virus Type 1 DNA and RNA in Long-Term Nonprogressors. <i>Journal of Infectious Diseases</i> , 1999, 179, 1542-1548.	1.9	25
142	DNA Sequence of the Long Terminal Repeat of Human Immunodeficiency Virus Type 1 Subtype A through G. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 485-488.	0.5	25
143	Initiation of Therapy during Primary HIV Type 1 Infection Results in a Continuous Decay of Proviral DNA and a Highly Restricted Viral Evolution. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 409-416.	0.5	25
144	Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy. <i>Aids</i> , 2001, 15, 1359-1368.	1.0	25

#	ARTICLE	IF	CITATIONS
145	Human APOBEC3G-mediated hypermutation is associated with antiretroviral therapy failure in HIV-1 subtype C-infected individuals. <i>Journal of the International AIDS Society</i> , 2013, 16, 18472.	1.2	25
146	IgG subclass reactivity against human immunodeficiency virus (HIV) and cytomegalovirus in cerebrospinal fluid and serum from HIV-infected patients. <i>Journal of Medical Virology</i> , 1988, 25, 17-26.	2.5	24
147	Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 673-677.	1.5	24
148	Antiretroviral treatment for HIV infection: Swedish recommendations 2016. <i>Infectious Diseases</i> , 2017, 49, 1-34.	1.4	24
149	Evolution, correlation, structural impact and dynamics of emerging SARS-CoV-2 variants. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 3799-3809.	1.9	24
150	Prevalence and Risk Factors for HTLV-II Infection in 913 Injecting Drug Users in Stockholm, 1994. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 15, 381-386.	0.3	24
151	Hepatitis C virus infection in individuals with or without human immunodeficiency virus type 1 infection. <i>Infection</i> , 1990, 18, 347-351.	2.3	23
152	High Mobility Group Box Protein-1 in HIV-1 Infection: Connecting Microbial Translocation, Cell Death and Immune Activation. <i>Current HIV Research</i> , 2011, 9, 6-10.	0.2	23
153	Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naïve HIV-1 infected patients. <i>Retrovirology</i> , 2012, 9, 81.	0.9	23
154	A high rate of HIV-1 acquisition post immigration among migrants in Sweden determined by a CD4 cell decline trajectory model. <i>HIV Medicine</i> , 2017, 18, 677-684.	1.0	23
155	Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts $\leq 200\text{ Cells}/\mu\text{L}$: TB-HAART Study, a Randomized Clinical Trial. <i>PLoS ONE</i> , 2015, 10, e0122587.	1.1	23
156	Hepatitis C Virus Replication in Liver and Peripheral Blood Mononuclear Cells of Interferon- α -Treated and Untreated Patients with Chronic Hepatitis C. <i>Scandinavian Journal of Gastroenterology</i> , 1994, 29, 82-86.	0.6	22
157	Human Immunodeficiency Virus Type 1-Infected Patients with No Disease Progression Display Highavidity Antibody Production to Autologous V3 Sequences. <i>Journal of Infectious Diseases</i> , 1995, 171, 509-509.	1.9	22
158	The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 349-357.	0.8	22
159	Long-Term Efficacy of First Line Antiretroviral Therapy in Indian HIV-1 Infected Patients: A Longitudinal Cohort Study. <i>PLoS ONE</i> , 2013, 8, e55421.	1.1	22
160	Characterization of HIV-Specific CD4+ T Cell Responses against Peptides Selected with Broad Population and Pathogen Coverage. <i>PLoS ONE</i> , 2012, 7, e39874.	1.1	22
161	Sequence analysis of selected regions of the env (V3 loop and gp 41) and gag (p7) reading frames of Ethiopian human immunodeficiency virus type 1 strains. <i>Archives of Virology</i> , 1993, 128, 229-239.	0.9	21
162	Transmission of Hepatitis C Virus by Transfusion in Årebro County, Sweden, 1990-1992. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 449-452.	1.5	21

#	ARTICLE	IF	CITATIONS
163	Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models. <i>PLoS ONE</i> , 2010, 5, e13753.	1.1	21
164	Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. <i>Journal of Infectious Diseases</i> , 2013, 207, S101-S106.	1.9	21
165	Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia. <i>PLoS ONE</i> , 2018, 13, e0200505.	1.1	21
166	Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium. <i>Frontiers in Microbiology</i> , 2019, 10, 613.	1.5	21
167	Trends in Antiretroviral Therapy and Prevalence of HIV Drug Resistance Mutations in Sweden 1997-2011. <i>PLoS ONE</i> , 2013, 8, e59337.	1.1	21
168	Evaluation of a multiple peptide assay for typing of antibodies to the hepatitis C virus: Relation to genomic typing by the polymerase chain reaction. <i>Journal of Medical Virology</i> , 1995, 45, 50-55.	2.5	20
169	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016, 63, ciw519.	2.9	20
170	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	1.9	20
171	Effect of dolutegravir in combination with Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on people living with HIV who have pre-existing NRTI mutations. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 733-738.	1.1	20
172	Characterization of Inducible Transcription and Translation-Competent HIV-1 Using the RNAscope ISH Technology at a Single-Cell Resolution. <i>Frontiers in Microbiology</i> , 2018, 9, 2358.	1.5	20
173	Human Immunodeficiency Virus Type-1 Elite Controllers Maintain Low Co-Expression of Inhibitory Receptors on CD4+ T Cells. <i>Frontiers in Immunology</i> , 2018, 9, 19.	2.2	20
174	HIV-1 Sub-Subtype A6: Settings for Normalised Identification and Molecular Epidemiology in the Southern Federal District, Russia. <i>Viruses</i> , 2020, 12, 475.	1.5	20
175	Antigenic structure of the complete nonstructural (NS) 2 and 5 proteins of hepatitis C virus (HCV): anti-HCV NS2 and NS5 antibody reactivities in relation to HCV serotype, presence of HCV RNA, and acute HCV infection. <i>Vaccine Journal</i> , 1994, 1, 290-294.	2.6	20
176	Evidence of No Change in V3 Loop Antibody Recognition Pattern in HIV Type 1-Infected Ethiopians between 1988 and 1993. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 1551-1556.	0.5	19
177	Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam. <i>Infection, Genetics and Evolution</i> , 2012, 12, 448-452.	1.0	19
178	Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients. <i>Aids</i> , 2014, 28, 2319-2322.	1.0	19
179	Multiplexed next-generation sequencing and de novo assembly to obtain near full-length HIV-1 genome from plasma virus. <i>Journal of Virological Methods</i> , 2016, 236, 98-104.	1.0	19
180	Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort. <i>Aids</i> , 2018, 32, 161-169.	1.0	19

#	ARTICLE	IF	CITATIONS
181	Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes. <i>Frontiers in Microbiology</i> , 2018, 9, 1754.	1.5	19
182	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. <i>PLoS Pathogens</i> , 2020, 16, e1008264.	2.1	19
183	Altered Gut Microbiome under Antiretroviral Therapy: Impact of Efavirenz and Zidovudine. <i>ACS Infectious Diseases</i> , 2021, 7, 1104-1115.	1.8	19
184	Restriction of Hepatitis C Virus Heterogeneity during Prolonged Interferon- α Therapy in Relation to Changes in Virus Load. <i>Journal of Infectious Diseases</i> , 1996, 173, 992-996.	1.9	18
185	High Plasma Levels of Soluble Fas in HIV Type 1-Infected Subjects Are Not Normalized during Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 1379-1384.	0.5	18
186	Differences in adherence and motivation to HIV therapy—two independent assessments in 1998 and 2002. <i>International Journal of Clinical Pharmacy</i> , 2006, 28, 248-256.	1.4	18
187	Antiretroviral treatment of HIV infection: Swedish recommendations 2007. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 486-507.	1.5	18
188	Phylogenetic Analysis of Ethiopian HIV-1 Subtype C Near Full-Length Genomes Reveals High Intrasubtype Diversity and a Strong Geographical Cluster. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 471-474.	0.5	18
189	New subtype of HIV-1 in Ethiopia. <i>Lancet, The</i> , 1990, 336, 942-942.	6.3	17
190	Distinguishing Acute from Symptomatic Chronic Hepatitis C Virus (HCV) Infection by Site-Directed Serology of the HCV Structural Proteins. <i>Journal of Infectious Diseases</i> , 1995, 171, 1356-1359.	1.9	17
191	Quantification of HIV-1 proviral DNA from peripheral blood mononuclear cells using a high throughput four-competitor competitive PCR. <i>Journal of Virological Methods</i> , 1997, 69, 171-180.	1.0	17
192	Human and murine antibody recognition is focused on the ATPase/Helicase, but not the protease domain of the hepatitis C virus nonstructural 3 protein. <i>Hepatology</i> , 1998, 28, 219-224.	3.6	17
193	Long-Term Effects of Antiretroviral Combination Therapy on HIV Type 1 DNA Levels. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1249-1254.	0.5	17
194	Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response. <i>PLoS ONE</i> , 2013, 8, e61436.	1.1	17
195	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2869-2878.	1.3	17
196	Pulmonary stromal expansion and intra-alveolar coagulation are primary causes of COVID-19 death. <i>Heliyon</i> , 2021, 7, e07134.	1.4	17
197	DYNAMIC ANALYSIS OF HEPATITIS C VIRUS POLYMORPHISM IN PATIENTS WITH ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1997, 64, 170-172.	0.5	17
198	Levels of hepatitis C virus (HCV) RNA in serum and their relationship to levels of immunoglobulin M and G antibodies against HCV core protein. <i>Journal of Clinical Microbiology</i> , 1995, 33, 778-780.	1.8	17

#	ARTICLE	IF	CITATIONS
199	Recent Origin of Human Immunodeficiency Virus Type 1 Variants in Resting CD4+T Lymphocytes in Untreated and Suboptimally Treated Subjects. <i>Journal of Infectious Diseases</i> , 2001, 184, 1392-1401.	1.9	16
200	Treatment of HIV infection: Swedish recommendations 2009. <i>Scandinavian Journal of Infectious Diseases</i> , 2009, 41, 788-807.	1.5	16
201	<scp>HCV RNA</scp> decline in chronic <scp>HCV</scp> genotype 2 and 3 during standard of care treatment according to <scp>IL</scp>28B polymorphism. <i>Journal of Viral Hepatitis</i> , 2013, 20, 193-199.	1.0	16
202	PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context. <i>Bioinformatics</i> , 2017, 33, 3993-3995.	1.8	16
203	Delayed Treatment for People Living with HIV in China, 2004â€“2016: An Analysis of An Observational Cohort. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1809.	1.2	16
204	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatmentâ€“Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	2.9	16
205	Detection of Cell-Free Human Immunodeficiency Virus in Cerebrospinal Fluid by Using Immune Scanning Electron Microscopy. <i>Journal of Infectious Diseases</i> , 1989, 159, 1037-1041.	1.9	15
206	Relationship between cell-free viraemia, antigenaemia and antibody levels in HIV-1-infected Ethiopian patients. <i>Aids</i> , 1992, 6, 651-658.	1.0	15
207	Antiretroviral Treatment of Human Immunodeficiency Virus Infection: Swedish Recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 155-167.	1.5	15
208	Higher Prevalence of Predicted X4-Tropic Strains in Perinatally Infected Older Children With HIV-1 Subtype C in India. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, 347-353.	0.9	15
209	Mutational Heterogeneity in p6 Gag Late Assembly (L) Domains in HIV-1 Subtype C Viruses from South Africa. <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 80-84.	0.5	15
210	HIV-1 CRF07_BC transmission dynamics in China: two decades of national molecular surveillance. <i>Emerging Microbes and Infections</i> , 2021, 10, 1919-1930.	3.0	15
211	Whole-Genome Metagenomic Analysis of the Gut Microbiome in HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Frontiers in Microbiology</i> , 2021, 12, 667718.	1.5	15
212	Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Na ⁺ -ve HIV-1â€“Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 533-540.	0.5	14
213	Bilirubinâ€“A Potential Marker of Drug Exposure in Atazanavir-Based Antiretroviral Therapy. <i>AAPS Journal</i> , 2011, 13, 598-605.	2.2	14
214	Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-na ⁺ -ve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial. <i>Scandinavian Journal of Infectious Diseases</i> , 2013, 45, 543-551.	1.5	14
215	Multidimensional Clusters of CD4+ T Cell Dysfunction Are Primarily Associated with the CD4/CD8 Ratio in Chronic HIV Infection. <i>PLoS ONE</i> , 2015, 10, e0137635.	1.1	14
216	Prophylaxis and treatment of HIV-1 infection in pregnancy â€“ Swedish Recommendations 2017. <i>Infectious Diseases</i> , 2018, 50, 495-506.	1.4	14

#	ARTICLE	IF	CITATIONS
217	Distinct lipid profile, low-level inflammation, and increased antioxidant defense signature in HIV-1 elite control status. <i>IScience</i> , 2021, 24, 102111.	1.9	14
218	Efficacy of Human Leucocyte Alpha-Interferon Treatment for Chronic Hepatitis C Virus Infection. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 319-324.	1.5	13
219	Pronounced Anti-HIV-1 Activity of Foscarnet in Patients Without Cytomegalovirus Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 51-53.	0.3	13
220	The Anti-HBs Response After 2 Different Accelerated Intradermal and Intramuscular Schemes for Hepatitis B Vaccination. <i>Scandinavian Journal of Infectious Diseases</i> , 1999, 31, 93-95.	1.5	13
221	Inter-laboratory comparison of HCV-RNA assay results: Implications for multi-centre research. <i>Journal of Medical Virology</i> , 2003, 69, 195-201.	2.5	13
222	Follow-up of Antiretroviral Treatment in Liver Transplant Recipients with Primary and Chronic HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 13-19.	0.5	13
223	Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR. <i>Journal of Virological Methods</i> , 2005, 127, 100-107.	1.0	13
224	A structural equation modeling approach to the concepts of adherence and readiness in antiretroviral treatment. <i>Patient Education and Counseling</i> , 2007, 67, 108-116.	1.0	13
225	Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden. <i>Scientific Reports</i> , 2017, 7, 6371.	1.6	13
226	Antiretroviral treatment for HIV infection: Swedish recommendations 2019. <i>Infectious Diseases</i> , 2020, 52, 295-329.	1.4	13
227	Pattern of microbial translocation in patients living with HIV-1 from Vietnam, Ethiopia and Sweden. <i>Journal of the International AIDS Society</i> , 2014, 17, 18841.	1.2	13
228	Relation between GB virus C/hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products. <i>Gut</i> , 1999, 44, 274-278.	6.1	12
229	Long-Term Pattern of HIV-1 RNA Load in Perinatally Infected Children. <i>Scandinavian Journal of Infectious Diseases</i> , 1999, 31, 337-343.	1.5	12
230	Rapid and Simple Determination of Indinavir in Serum, Urine, and Cerebrospinal Fluid Using High-Performance Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 626-629.	1.0	12
231	Quantitative single cell methods that identify cytokine and chemokine expression in dendritic cells. <i>Journal of Immunological Methods</i> , 2001, 249, 207-222.	0.6	12
232	Persistence of earlier HIV-1 drug resistance mutations at new treatment failure. <i>Journal of Medical Virology</i> , 2002, 68, 473-478.	2.5	12
233	HIV-1 mutational pathways under multidrug therapy. <i>AIDS Research and Therapy</i> , 2011, 8, 26.	0.7	12
234	Evolution of fibrosis during HCV recurrence after liver transplantation – influence of IL-28B SNP and response to pegIFN and ribavirin treatment. <i>Journal of Viral Hepatitis</i> , 2013, 20, 770-778.	1.0	12

#	ARTICLE	IF	CITATIONS
235	Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam. <i>BMC Infectious Diseases</i> , 2016, 16, 759.	1.3	12
236	Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa. <i>Journal of Medical Virology</i> , 2017, 89, 106-111.	2.5	12
237	Quantitative humoral profiling of the HIV-1 proteome in elite controllers and patients with very long-term efficient antiretroviral therapy. <i>Scientific Reports</i> , 2017, 7, 666.	1.6	12
238	Antiretroviral potency of 4'-ethynyl-2'-fluoro-2'-deoxyadenosine, tenofovir alafenamide and second-generation NNRTIs across diverse HIV-1 subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2721-2728.	1.3	12
239	The Quest Trial, a paradigm of HIV collaborative research. <i>Nature Medicine</i> , 2000, 6, 1194-1194.	15.2	11
240	Impact of immunosuppression and region of birth on risk of cervical intraepithelial neoplasia among migrants living with HIV in Sweden. <i>International Journal of Cancer</i> , 2016, 139, 1471-1479.	2.3	11
241	Monophylogenetic HIV-1C epidemic in Ethiopia is dominated by CCR5-tropic viruses—an analysis of a prospective country-wide cohort. <i>BMC Infectious Diseases</i> , 2017, 17, 37.	1.3	11
242	Microfluidic centrifugation assisted precipitation based DNA quantification. <i>Lab on A Chip</i> , 2019, 19, 1657-1664.	3.1	11
243	HIV-1 Subtype C with PYxE Insertion Has Enhanced Binding of Gag-p6 to Host Cell Protein ALIX and Increased Replication Fitness. <i>Journal of Virology</i> , 2019, 93, .	1.5	11
244	Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. <i>PLoS ONE</i> , 2017, 12, e0178942.	1.1	11
245	Relationship between the occurrence of virus in plasma and cerebrospinal fluid of hiv-1 infected individuals. <i>Journal of Medical Virology</i> , 1989, 27, 258-263.	2.5	10
246	Treatment of chronic hepatitis B infection: An update of Swedish recommendations. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 436-450.	1.5	10
247	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010. <i>Scandinavian Journal of Infectious Diseases</i> , 2011, 43, 411-423.	1.5	10
248	Overcoming obstacles to late presentation for HIV infection in Europe. <i>HIV Medicine</i> , 2011, 12, 246-249.	1.0	10
249	Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. <i>AIDS Research and Therapy</i> , 2011, 8, 21.	0.7	10
250	Minority Drug-Resistant HIV-1 Variants in Treatment Na ⁺ ve East-African and Caucasian Patients Detected by Allele-Specific Real-Time PCR. <i>PLoS ONE</i> , 2014, 9, e111042.	1.1	10
251	Transmitted drug resistance to NRTIs and risk of virological failure in na ⁺ ve patients treated with integrase inhibitors. <i>HIV Medicine</i> , 2021, 22, 22-27.	1.0	10
252	Post-migration acquisition of HIV: Estimates from four European countries, 2007 to 2016. <i>Eurosurveillance</i> , 2021, 26, .	3.9	10

#	ARTICLE	IF	CITATIONS
253	Complex Mutation Pattern of Omicron BA.2: Evading Antibodies without Losing Receptor Interactions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5534.	1.8	10
254	A Cell-Binding Arg-Gly-Asp Sequence Is Present in Close Proximity to the Major Linear Antigenic Region of HCV NS3. <i>Biochemical and Biophysical Research Communications</i> , 1994, 202, 1352-1356.	1.0	9
255	Prevention of nosocomial transmission of hepatitis C virus. <i>Lancet, The</i> , 1995, 346, 190.	6.3	9
256	Sequence Note: Full-Length Sequence of Human Immunodeficiency Virus Type 1 Subtype A, Recombined with Subtype C in the <i>env</i> V3 Domain. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 289-292.	0.5	9
257	Efficacy of nelfinavir-based treatment in the central nervous system of HIV-1 infected patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 371-374.	1.5	9
258	Use of InfCare HIV to identify and characterize suboptimally treated HIV patients at a Danish HIV clinic: A cross-sectional cohort study. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 108-114.	1.5	9
259	Long-Term Efficacy and Safety of Atazanavir/Ritonavir Treatment in a Real-Life Cohort of Treatment-Experienced Patients with HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 564-573.	0.5	9
260	Role of translocated bacterial flagellin in monocyte activation among individuals with chronic HIV-1 infection. <i>Clinical Immunology</i> , 2015, 161, 180-189.	1.4	9
261	Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. <i>HIV Medicine</i> , 2015, 16, 297-306.	1.0	9
262	Increase in transmitted drug resistance in migrants from sub-Saharan Africa diagnosed with HIV-1 in Sweden. <i>Aids</i> , 2018, 32, 877-884.	1.0	9
263	HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2662-2668.	1.1	9
264	The neurotoxin-like sequence of human immunodeficiency virus GP120: A comparison of sequence data from patients with and without neurological symptoms. <i>Virus Genes</i> , 1993, 7, 23-31.	0.7	8
265	No Association of HIV Type 1 Long Terminal Repeat Sequence Pattern with Long-Term Nonprogression and in Vivo Viral Replication Levels in European Subjects. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 609-617.	0.5	8
266	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007. <i>Scandinavian Journal of Infectious Diseases</i> , 2008, 40, 451-461.	1.5	8
267	Monitoring the efficacy of antiretroviral therapy by a simple reverse transcriptase assay in HIV-infected adults in rural Vietnam. <i>Future Virology</i> , 2012, 7, 923-931.	0.9	8
268	Efficacy of Antiretroviral Therapy Switch in HIV-Infected Patients: A 10-Year Analysis of the EuResist Cohort. <i>Intervirolgy</i> , 2012, 55, 160-166.	1.2	8
269	Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort. <i>BMC Infectious Diseases</i> , 2013, 13, 537.	1.3	8
270	Molecular Dating of HIV-1 Subtype C from Bangladesh. <i>PLoS ONE</i> , 2013, 8, e79193.	1.1	8

#	ARTICLE	IF	CITATIONS
271	Suppressive antiretroviral therapy associates with effective treatment of high-grade cervical intraepithelial neoplasia. <i>Aids</i> , 2018, 32, 1475-1484.	1.0	8
272	Contagiousness in treated HIV-1 infection. <i>Infectious Diseases</i> , 2021, 53, 1-8.	1.4	8
273	Symptomatic Patients without Epidemiological Indicators of HIV Have a High Risk of Missed Diagnosis: A Multi-Centre Cross Sectional Study. <i>PLoS ONE</i> , 2016, 11, e0162503.	1.1	8
274	Characterization of the Upper Respiratory Bacterial Microbiome in Critically Ill COVID-19 Patients. <i>Biomedicines</i> , 2022, 10, 982.	1.4	8
275	Detection of hepatitis G virus/GB virus C after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1998, 22, 499-501.	1.3	7
276	Variability and Immunogenicity of Human Immunodeficiency Virus Type 1 p24 Gene Quasispecies. <i>Vaccine Journal</i> , 2000, 7, 377-383.	2.6	7
277	Antiretroviral treatment of HIV infection: Swedish recommendations 2005. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 86-103.	1.5	7
278	Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma. <i>HIV Medicine</i> , 2009, 10, 111-115.	1.0	7
279	Evaluation of etravirine resistance in clinical samples by a simple phenotypic Test. <i>Journal of Medical Virology</i> , 2013, 85, 703-708.	2.5	7
280	Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. <i>Infectious Diseases</i> , 2016, 48, 93-98.	1.4	7
281	Integrative proteo-transcriptomic and immunophenotyping signatures of HIV-1 elite control phenotype: A cross-talk between glycolysis and HIF signaling. <i>IScience</i> , 2022, 25, 103607.	1.9	7
282	Genome-scale metabolic models for natural and long-term drug-induced viral control in HIV infection. <i>Life Science Alliance</i> , 2022, 5, e202201405.	1.3	7
283	Coexisting members of HIV-1 p17 gene quasispecies represent proteins with distinct antigenicity and immunogenicity. <i>Aids</i> , 1998, 12, 1973-1981.	1.0	6
284	High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 624-632.	1.5	6
285	Factors influencing the efficacy of rilpivirine in HIV-1 subtype C in low- and middle-income countries. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 367-371.	1.3	6
286	A21 HIV-1 sub-subtype F1 outbreak among MSM in Belgium. <i>Virus Evolution</i> , 2017, 3, .	2.2	6
287	A viral genome wide association study and genotypic resistance testing in patients failing first line antiretroviral therapy in the first large countrywide Ethiopian HIV cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 569.	1.3	6
288	Strain-specific effect on biphasic DNA binding by HIV-1 integrase. <i>Aids</i> , 2019, 33, 588-592.	1.0	6

#	ARTICLE	IF	CITATIONS
289	Optimal probability weights for estimating causal effects of time-varying treatments with marginal structural Cox models. <i>Statistics in Medicine</i> , 2019, 38, 1891-1902.	0.8	6
290	Letter to the editor: Pre-exposure prophylaxis for HIV in Europe: The need for resistance surveillance. <i>Eurosurveillance</i> , 2017, 22, .	3.9	6
291	Kinetics of β^2 -Chemokine Levels during Anti-HIV Therapy. <i>Antiviral Therapy</i> , 1999, 4, 109-115.	0.6	6
292	Fine analysis of intrathecally synthesized anti-HIV IgG1-4 by peptide mapping. <i>Journal of the Neurological Sciences</i> , 1990, 100, 31-36.	0.3	5
293	Site-directed serology of HIV-1 subtype B infection: relation between virus specific antibody levels and disease progression. <i>Clinical and Experimental Immunology</i> , 1996, 106, 35-39.	1.1	5
294	Smaller Amounts of Antiretroviral Drugs Are Needed When Combined with an Active Ribozyme against HIV-1. <i>Molecular Therapy</i> , 2001, 3, 531-535.	3.7	5
295	Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir. <i>Journal of Medical Virology</i> , 2005, 76, 447-451.	2.5	5
296	Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure. <i>HIV Medicine</i> , 2007, 8, 504-510.	1.0	5
297	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish recommendations 2013. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 401-411.	1.5	5
298	HIV elite control is associated with reduced TRAILshort expression. <i>Aids</i> , 2019, 33, 1757-1763.	1.0	5
299	HIV-1 subtype C epidemic in Ethiopia. <i>Aids</i> , 1997, 11, 1897.	1.0	5
300	Antibody production against hepatitis C virus core and nonstructural 3 proteins is highly sensitive to deficits in T-cell function. <i>Vaccine Journal</i> , 1997, 4, 104-106.	2.6	5
301	T cell stimulation remodels the latently HIV-1 infected cell population by differential activation of proviral chromatin. <i>PLoS Pathogens</i> , 2022, 18, e1010555.	2.1	5
302	Broad Spectrum of Time of Detection, Primary Symptoms and Disease Progression in Infants with HIV-1 Infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2001, 20, 0159-0166.	1.3	4
303	Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. <i>Journal of Medical Virology</i> , 2009, 81, 1-8.	2.5	4
304	A high occurrence of late presenters and missed HIV diagnosis in clinical care in Sweden. <i>Journal of the International AIDS Society</i> , 2010, 13, P169.	1.2	4
305	HIV-1 fitness landscape models for indinavir treatment pressure using observed evolution in longitudinal sequence data are predictive for treatment failure. <i>Infection, Genetics and Evolution</i> , 2013, 19, 349-360.	1.0	4
306	Prediction of coreceptor usage by five bioinformatics tools in a large Ethiopian HIV-1 subtype C cohort. <i>PLoS ONE</i> , 2017, 12, e0182384.	1.1	4

#	ARTICLE	IF	CITATIONS
307	Longer-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinics. <i>Journal of Infection</i> , 2019, 78, 402-408.	1.7	4
308	The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. <i>Aids</i> , 2019, 33, 315-326.	1.0	4
309	Challenges in modelling the proportion of undiagnosed HIV infections in Sweden. <i>Eurosurveillance</i> , 2019, 24, .	3.9	4
310	Novel Naturally Occurring Dipeptides and Single-Stranded Oligonucleotide Act as Entry Inhibitors and Exhibit a Strong Synergistic Anti-HIV-1 Profile. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1103-1116.	1.8	4
311	Genotyping of hepatitis C virus performed by type-specific PCR in comparison to nucleotide sequencing of NS5 and core regions. <i>Research in Virology</i> , 1997, 148, 233-237.	0.7	3
312	Similar HIV-1 Subtype A V3 Loop Sequences Are Found in Dual HIV-1/HIV-2 and HIV-1-Only Seropositives in Ghana. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 775-779.	0.5	3
313	Minor viral population with drug-resistant mutation and risk of persistent low-level viremia or "blips"™ in HIV-1 subtype C. <i>Aids</i> , 2014, 28, 2635-2636.	1.0	3
314	Effect of therapy switch on time to second-line antiretroviral treatment failure in HIV-infected patients. <i>PLoS ONE</i> , 2017, 12, e0180140.	1.1	3
315	MiDRMpol: A High-Throughput Multiplexed Amplicon Sequencing Workflow to Quantify HIV-1 Drug Resistance Mutations against Protease, Reverse Transcriptase, and Integrase Inhibitors. <i>Viruses</i> , 2019, 11, 806.	1.5	3
316	High-throughput sequencing reveals a high prevalence of pretreatment HIV-1 drug resistance in Sweden. <i>Aids</i> , 2021, 35, 227-234.	1.0	3
317	Decreased Phenotypic Susceptibility to Etravirine in Patients with Predicted Genotypic Sensitivity. <i>PLoS ONE</i> , 2014, 9, e101508.	1.1	3
318	Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations. <i>Pathogens</i> , 2022, 11, 546.	1.2	3
319	Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction. <i>PLoS ONE</i> , 2010, 5, e9044.	1.1	2
320	Optimizing background therapy in treatment-experienced HIV-1 patients by rules-based algorithms and bioinformatics. <i>Future Virology</i> , 2012, 7, 749-757.	0.9	2
321	497 SPONTANEOUS CLEARANCE OR CHRONIC EVOLUTION OF HCV IN HIV/HCV CO-INFECTED PATIENTS " INFLUENCE OF THE IL28B GENOTYPE. <i>Journal of Hepatology</i> , 2013, 58, S204.	1.8	2
322	Assessing cervical intraepithelial neoplasia as an indicator disease for <scp>HIV</scp> in a low endemic setting: a population-based register study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2017, 124, 1680-1687.	1.1	2
323	Cytotoxic Lymphocytes Target HIV-1 Gag Through Granzyme M-Mediated Cleavage. <i>Frontiers in Immunology</i> , 2021, 12, 669347.	2.2	2
324	Peripheral blood CD4+CCR6+ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals. <i>Communications Biology</i> , 2022, 5, 357.	2.0	2

#	ARTICLE	IF	CITATIONS
325	Combination Treatment for Hepatitis C Can be Hazardous in Patients Co-Infected with HIV. <i>Antiviral Therapy</i> , 1998, 3, 233-234.	0.6	2
326	Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds. <i>Antiviral Research</i> , 1992, 19, 353-359.	1.9	1
327	Variability of the E2/NS1 Region of Swedish Hepatitis C Virus Strains and Its Correlation to Genotypes. <i>Scandinavian Journal of Infectious Diseases</i> , 1994, 26, 255-261.	1.5	1
328	Cerebrospinal fluid analyses in HIV patients: a longitudinal study through six years. <i>European Journal of Neurology</i> , 1997, 4, 576-585.	1.7	1
329	Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients. <i>Journal of the International AIDS Society</i> , 2010, 13, P31-P31.	1.2	1
330	Emergence of unique recombinant forms (URFs) in Indian HIV-1 epidemic: data from nationwide clinical cohort between 2007 and 2011. <i>Retrovirology</i> , 2012, 9, .	0.9	1
331	AIDS and HIV Infection after Thirty Years. <i>AIDS Research and Treatment</i> , 2013, 2013, 1-3.	0.3	1
332	IgG subclasses of antibodies reacting with HIV and myelin basic protein in CSF from HIV infected patients. <i>Journal of Neuroimmunology</i> , 1988, 17, 258-259.	1.1	0
333	Non-specific reactivity in HIV antigen assay of sera from organ transplant recipients. <i>Infection</i> , 1989, 17, 168-169.	2.3	0
334	Treatment of HIV-1 Infected Patients with Peptide T. <i>Antiviral Chemistry and Chemotherapy</i> , 1990, 1, 349-354.	0.3	0
335	Switching Antiretroviral Therapy From an Enzyme-Inducing Drug. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 637-638.	1.0	0
336	Use of genotypic assays for the detection of antiretroviral resistance: a legal proceeding, Rome, 22â€“23 april 2002. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 5-5.	1.5	0
337	Authors' Response to â€œEarly Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir as Maintenance Monotherapyâ€œ. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, 118-119.	0.9	0
338	Time on drug analysis based on real life data. <i>Journal of the International AIDS Society</i> , 2014, 17, 19790.	1.2	0
339	P770 LOWER UPTAKE OF HCV TREATMENT THAN HIV TREATMENT IN HIV/HCV CO-INFECTED PATIENTS. <i>Journal of Hepatology</i> , 2014, 60, S327.	1.8	0
340	A5â€œNear full-length HIV-1 genome sequencing in newly diagnosed individuals in Sweden. <i>Virus Evolution</i> , 2019, 5, .	2.2	0
341	Coreceptor Tropism and Maraviroc Sensitivity of Clonally Derived Ethiopian HIV-1C Strains Using an in-house Phenotypic Assay and Commonly Used Genotypic Methods. <i>Current HIV Research</i> , 2018, 16, 113-120.	0.2	0
342	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0

#	ARTICLE	IF	CITATIONS
343	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0
344	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0
345	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0
346	Chromatin maturation of the HIV-1 provirus in primary resting CD4+ T cells. , 2020, 16, e1008264.		0